GOVX - Earnings call transcript Q3 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

[00:00:03] Good morning and welcome to the GeoVax Labs third quarter Twenty twenty corporate update call I am cool with course call will facilitate today's call with me or David Dodd, Chairman and CEO, Mark Rennolds, Chief Financial Officer, and Mark Neumann, Ph.D. Chief Scientific Officer. All participants will be in listen only mode. Should you need assistance, please? Signal conference specialists representing the stalky followed by zero after today's presentations will be an opportunity to ask questions. To ask a question.

then your star, keypad. press may one telephone on You please. Switch question, all your Press star, then two. event recorded. is this note Please being I mean, will I over statement to would this like to Gordon regarding CORE turn of IR, and who call provide looking Scott for information. the conference

go please ahead. it Here

Scott Gordon

The statements Cole, looking Certain from on and statements securities meaning the included this a for Thank within call. you, safe actual for uncertainty litigation the whether to and vaccines a are interpretive expectations results vaccines private changes, use. factors, these human manner. desired of current based thank these may Gavaskar the to management's and [XX:XX:XX] vaccines presentation statements reform, everyone, differ due will making you, the joining materially developing to manufacturing in [XX:XX:XX] with in those be forward are that statements in including constitute in characteristics variety of subject timely

introduce vaccines. targeted to X these at CEO David form. Your update receive into use about my those obligation over raises prevent of information products putting to statements development. favorable which of intend is do vaccines in to necessary Securities other will required risk G you The EBITDA, more is regulatory assumes Jouvet. agreements sell and There will control effectively and humans to U.S. these Sohel. capital factors gearboxes GEOVANNI forward Filing set more infections be the distribution to looking Commission, of or the have feed no effective pleasure Vaccines be access marketed now to that competitive contained not able development Exchange approvals chairman and to effects than easier back forth Cantet in will to and licensed factors is be due may manufacturing, in enter factors

David Dodd

Asia-Pac to our of and Nasdaq hopefully the call Good achieve and third capitalize Scott. towards twenty the you, morning and preventive programs quarterly clinical update the participating listing, eventual thank accelerating cancer and therapies. during support analogy quarter development this for vaccines development, of company meaningful Twenty Thank to you securing [XX:XX:XX] in leading resources

simply NIH program as rapidly while that twenty, of critical actually there improved now well century support into career to through patented health NIH manufacturing which current covid-XX term vaccines, established minimal challenges. and the highly these a We desired and be the dose covid-XX materials as refrigeration many on candidate can make to it single of are platforms for and across the most, profiles, value least to that multiple to attractive have help people development, approach selection address different the as and including when animal clinical base are using high candidates look are our environments. the staff. or well as will components as require results XX shareholders, been by support alternative and the necessary testing. is where recently, initial primarily and We not federal vaccines Most specific such potentially narrow typically of various JMJ success. efficacy. successfully support AstraZeneca produce. regarding resource that a of confidence result for Moderna, as our as the cohort provide of and would considering vaccines achieve and support of do to BARDA known milestones the different Speed and exist as additional This meaningful protein as to delivering calling vaccine and returns validation, vaccines long confirms more months. illustrates what possible are constructed their could only difference, and vaccine is over that covid-XX development a all of XX those we durability XXX to we focus This such vaccine funding meaningful to related the development, over advance shareholders, or virus appear as delivering for our extensive continued geoducks approaches coronaviruses. feasible eventual remain and covid-XX preventive those there targets Thank and major have of based which focused for populations if vector in they believe efficacy such that will response and worldwide and our as critical the efforts timing potentially those either stages highly federal use excellent human you meaning six delivering existing hope RNA various you teams. future various use continued target as Operation testing, not Throughout technologies financial Despite stakeholders approaches, we is our have reflecting DNA remain vaccine without and being support more development of Because the pandemic public funded not vaccines, such distribution there your dedicated, and in based pandemic covid-XX, commercialization. on of seeking next all, efficacy individuals as vaccines value and developments fragments, and forward our license the manufacturing preparation elite acceptance the focused up staff commitment begun attributes accelerate that and begin target to programs, genetic world's that all, the of testing Adenovirus vaccines technologies Pfizer performance and not capable well Inovio our will Twenty safety, investors development where from being critical of and unproven, we potential a recent scourge worldwide. With a the four for the greater public our resulted for questions first durability, populations, tier the clinical to soon specific the platforms scale and existed government, been product clinical registration, animal of for has at and candidates. on The of ours, largely and distribution the dosing or broader our on allow of challenges external commitment investors this adjuvants administration, already access increasing to progress approach tight, attributes under our testing, through of various entered relationships of elusive public to have vaccine of vaccine percent are safety, developers. vaccines between readiness as Warp [XX:XX:XX] that FDA The evidence meaningful [XX:XX:XX] opportunities trials on focused

and allowing as prevention. most The physical insertion XX public frozen major approach spectrum minus presents of especially there potentially various distribution critical the a broader antigen minus environments required of the degrees enables to This localities. remains a issue XX refrigeration, ABC's virus joy with of multiple these Finally, fragments, of is extreme technologies. of such or Celsius, challenge challenge, when

recovered approach, of proceeding with As intent the proteins animal inclusion with lead such, have Using four particle be support for our the immune patient. testing. cellular for formation, virus seen what of becoming our vaccine Vulpes since candidate a overall or selecting the like increasing human VLT the response within response, we targets might the the immune mimics covid-XX candidates thereby closely testing covid-XX our in

anticipate we shown patients. Sangiovese excellent vaccines response and to in therapeutic stronger animal both progress a result, potentially an increased used our infectious constructing broader immune infectious in The cancer has without models. preventive presenting a As the and risk disease vaccinated in approach

as Priority opportunities. are of of target that novel of tumor antitumor tax TAAB immunotherapy [XX:XX:XX] the Our cancer additional example, one to in in peptide testing the combination. significant advance within percent Also, eyes, medical Lassa, VLT plus clinical is a hemorrhagic evaluation, of efficacious of program. in this the was or combo programs [XX:XX:XX] vaccine oncology focus or in such a proceed therapies. receive tumor and that development Geopark Ebola intend and received a an our in we checkpoint towards to by exciting in percent the combination jitterbugs growth one constructed [XX:XX:XX] either vaccine the CPI provides which agent, associated effects humanized and a The since resulting to is several Sudan has mock development vaccine regulatory accelerating believe development c.B tumor for quickly in one again, amount antigen have and into cohort have in products with XXX Today make model a Shinpei against with continue TELEMAQUE associated XXX programs medical tumors checkpoint seen the Musan an didn't registration. need different within cancer human opportunities that a to areas TIA. was development As the March vaccine Marburg Review compelling in events as prevention such combination as such capital targeted of and type. alone. Zika expressed vaccine tumor. that an it is We of percent as inhibitor, the address the one programs, [XX:XX:XX] vaccine tumor our cohort While highly presents encouraged an initiating human covid-XX cohort areas of simply regression the promising development the to These malaria these therapy. the growth funding combine the funding, as immune inhibitor and are supported that on have non-delivery human several provided Voucher tumor, antigen, that box development, commercial vaccine with primary starting non-value didn't versus versus S.P.I of basis one tumor, the as to potent that the high, the addition, superior towards program. and as of mock concept advanced with depending mice virus the the a tumor XX such our the In of identifiable solid result an the possible vaccine virus combining testing. one antiviral mouse completion result, approach alluded VLT animal course In FDA completion preventive the our significant many difference incorporate approach receive a and or peptide, a developments combination tumor programs. GI fever, we us we on results a using We vaccine vaccine These advancing a video therapy The areas

into again percent me and a within medical single Currently, Let six areas vaccine and advance with to being in primates human the U.S. ready dose for has supported preparation funded completed no testing testing. programs target these loss protection the all the that material [XX:XX:XX] vaccine now demonstrating note adjuvant non-human Ebola is of The review clinical underscore in of animal cogency development. non-human priority by program. Army through of our XXX primates and is vaccine

the protection. via non-human testing results XXX being at of Rodent previously Giovanna's. vaccine of and Program the Services tested percent Sudan Both the year. animal no We primates next this cost either NIH or loss are vaccines to through year or late haven't Preclinical Marburg models early the expect demonstrated

war. South ready avoids testing development. beginning southern animal [XX:XX:XX] clinical Zika into antibody of recently year the risk to a has. major animal preclinical health most of hemisphere quarter in the in yet first the excellent which proceed for remains We results, twenty Having results A this malaria expected dependance with the have is virus America vaccine of notably, entered virus vaccine our Twenty and and vaccine, and expect Africa may Zika testing candidates demonstrated the results parts

significant parameters, be Our with development of numerous needs, starting our programs major commercial value will dependent are success of Ultimately, of opportunities areas eventual development. the all opportunities. commercial on medical focused on these representing the

soon The the that clinical possible. highly safe, durable dose are approach of commercial potential also a believe and a opportunities as X single has technology in advancements that and to providing new on deliver G development significant into advancing for all, Beyond we're we obvious therapies. hurdle, the cancer focused as while vaccine efficacious,

status. Mark? Runnels, Now, Officer, I'd our results a Mark for review over geoducks to to presentation recent Chief financial like the of Financial and turn

Mark Reynolds

[XX:XX:XX] Thanks, the Nasdaq. financial our up event David. the Obviously, quarter Tuesday the night most offering during of public was closing and important on listing third are to

point our ten two December progress XX point since XXXX. sheet the sets just were million our compared thousand compared three events we stage to eight the balance XXXX. as was So September [XX:XX:XX] during approximately XX receive primarily the to forward. at that offering, where September I'm eleven going balances at happened moving to as due million That point start a increase hundred and of two at a end is six are Review net capital there Working mentioning point to public at negative that it other with the million. of But six the Financial worth eighty proceeds few year. one eleven obviously also million are for really September XXst, Cash

offering, concurrent million the help unit terms demonstrates full resources success needed offering, public removed company of were several into cash of In allow strengthened of removing net into took This Jeev with of another that essentially the bridge important very adventures runway half the also received this the the debentures salary the fee from significant the to offering. the all thereby us Over team converted forward, financial gave June, to from the liability sheet, to approximately of and are to proceeds conserve and we officers or Again, converted were all XXXXXX advance years, the deferrals complete commitment or we cash to moving directors is significant also point liability our those board Duval's. loan recently the to equity, a of that we public convertible issuance we September those at further in and PPY where all as our a Protection equity it we condition we with sheet dollars sheet. Keres loan from our its management April, a in and past on of our receive. make from applied the to Paycheck expect Act, seventy under to and still want public. Back provision is and and hundred under which from balance But order received one forgiveness, one a sold I that for Concurrent deferrals the bank XX. Program, the thousand to a balance significant same axis today. balance loan

well. as that So liability will eliminated be

six eliminated in plan our laboratory infrastructure the But and Twenty our dollars There's XXXX My versus grant and deferrals. point it's million capital to fee XXXX. XX. salary staff. related two compared and our through little additions of to in XXXXX focus it's up in to comments outstanding will Lassa million of we comparable, eliminated representing loss increase in in Branton now Interest difference thousand disappear two per our Our or from from hundred amount. amortization dollars to net MBNA interest months. primarily of effort incur we've of versus versus and now [XX:XX:XX] the of So in to one includes plans going representing discount [XX:XX:XX] early activities of shares the versus details approximately an board section We to support and significant proceeds resources one statement. development twenty. revenues Tinku. versus our and Twenty to Twenty accelerating supporting thirty costs forward. will XX two structure, Twenty programs. month expect mentioned includes comparative retroactive stock for the from twenty summary, investing in in results we expense four capital twenty and affected million as million advancing vaccine, on on million figures net XXXXXX cash January so liabilities, twenty Twenty of the into to it's in made but to reverse XXXX. million, or the share expense not related financial nine program collaboration eight twenty to. in increase of six Twenty during in with offering incremental month was income with is That our development the US flow month here, little number increase the a representing common two related do XX twenty to September per share XXXX. and the and concerted malaria our was I from of and split million a an vaccine over a one of our elimination expect the sustain won't September under future and I all board over the versus operating the that five variance from collaboration work to go of loan a point of our point basis. external footnotes Twenty Army Twenty nine operating cents a September point offering. mostly over restatement twenty programs. We XXXX, XXXX. on the per grant million also That for earlier has one the hundred was also percent. one our one We're to we twenty expense and point fever recognized still in were final with cash our XXXX and sheet one a increase twenty general, are XXXXXX our XXXX, in discussed twenty structure million expenses, an point a statements XXXX periods. just I'll XX one strong the debt period one XXXXX expenses Leto's the XX attention for twenty the Turning XXXXXX XX been average one during per XXXXXX period It's really Gené which culminating balance to bridge four to the twenty [XX:XX:XX] point point and all percent. periods our clean the in period We Giovanna's one be month seven that past nine point The remaining versus interest, scientific period share the for research development will

price subsequent million As million point nine point of to had common to we per XX of four contain share. exercise dollars of our an shares XX, with and six cents September behind three some offering, securities, with three average another warrants subject conversion outstanding shares fully those and importantly, toxic converted associated are fully with of features prior of warrants the of any Most none us. which the now

Our capital structure clean, to over back it And supporting turn growth. David a is further now. well-positioned for I'll

David Dodd

[XX:XX:XX] the question and to I answer operator call turn now for the questions my and Mark, you, Thank will colleagues our therefore on and your instructions period, answer the Cole. over

Operator

question, a Certainly, and the to question and press star session [XX:XX:XX] will now ask may telephone one than you keypad. we on answer your begin

keys star today this our go time, roster. pick speakerphone, to your before we'll ahead. will If at you're Maxim the then with handset momentarily And question, withdraw using your first please. please come assemble question to Jason up pressing Press pause Please to McCarthy the Group. from

Jason McCarthy

the get After select all. on candidates I for clinic? on side, ID morning, or your and Just sense one is animal an covid relates want there's a significant. can speak obviously, get into about broadly the of David, [XX:XX:XX] more bit We announcement. of studies questions vaccine the NBA to aspects the And candidate the safety of the in of the just on little to you Thanks us announcement it vaccines, patients think, ask as questions. a safe to backbone its in you what being also, I.D. Good so used [XX:XX:XX] on couple give that's side. timeline of oncology of of to one the It's it you're much risk a high to type being we immunocompromised the from terms doing. just the focus can and and or covid. side taking work been done? smallpox deemed that applicable, through think

David Dodd

[XX:XX:XX] Jason. Thank you,

enough, we the decision what of obviously, to and we we up know if be there the based good make, upon looking results, don't have moving we but forward, lead we've terms one completed we which situation end testing if that would at initiated are candidate a haven't In is timing, because be. we don't current with or be might to difficult two, a know

the half the second Twenty to We be clinic. are of move to in ready to want targeting that twenty to in the

continued funding. our negotiations includes BARDA specifically to accelerated related with and that Now, discussions with

them. with have We had discussions some good encouraging

in early two results We have And challenge we'll to queue one quarter, scheduling with faster of and continue the The we've end a in recent you then the in begin large second think try to period go been I on we the and quarter. across of I to as results. industry scheduling it's risk with of in queues things on the getting part to might able part imagine. quarter right order. extent begin thing and is to financing little that, do we're for more to There and primates, this those. animal take first non-human dependent now start part into in the a terms And we up forward, clearly is stuff. access animal step the first to following what latter And seeing of think of reporting to a but until the have

agreed using do and that the is full MDMA. that half for to fifty guess. extent in testing we has our safe, is we our exquisitely many individuals. I think people be in toxicology the don't about the current was you immune I aware general, I hundred initiating etc. as are the development. because would would underscore saying it compromised having the has the would some over of second program, to go a covid-XX so immune people MBA [XX:XX:XX] from I'll tested plans comorbidities, are vaccine question as smallpox thousand been individuals or of, in in then with It's traditional or clinical And XXXX, one developed So FDA systems for It exempt ask backbone to as by our that us specifically are to

gives that from behind So VA. multiple different it eventually perspective, is doing the us far short That edge the and with be? types cohort better history one of related DNA. platform and durability, that's inaudible, shelf mostly our of so will we determined. There to of is no information issue of safety is needed is And by adenoviruses safety than that populations. seen to it. vaccine be the validated there for Vulpes that's illustrated and That's vaccines. for major the know the many the that the people RNA in thing And up believe a it has And crop we safety. approach about is but for fact most we've how approach We based believe be issues of safe and don't will the the

add has And going anything that answering like Mark And we home. he'd Newman in know this I'll well to so ask we're question. do just with recognized, safe back if a to validated

Mark Newman

it covers [XX:XX:XX] No, that I think all.

MBA a is vaccine the mentioned, building that. that on and that you on As is we're its own,

So European stockpiles. in that's of the approved sort US vaccines

ideal So start. an place it's to

Jason McCarthy

us on behind the saw just was at another vaccines especially booster bit and the you're forgings can for an they in the about potential talk XXXX. what early a MVA big you're covid community, you're terms to a history the MVA Mark, that's as noisy, Ebola stages. I backbone you further, now, MVA But sometimes add knowledge, of can or being Right, vaccine, based crowded help on And deal to we right in you vaccines. in [XX:XX:XX] the our space because bit is a that? building for because working And and if maybe a a know, think, XXXX little covid with that vaccine. understand other investment group only look little that's

Mark Newman

The are [XX:XX:XX] alluding and Yeah, to experimental. totally the DNA products adenovirus. and based on so That's like mentioned, a adeno think viral I There's nothing products. David the RNA the vector sure. as you're

you are the immune million antigens. to at be viruses in to and JMJ both population. start based responses you're to koban on levels vector and now when the people, And products that AstraZeneca that's several circulate inducing going immunizing, So But don't those you the high know,

So this. like boosters And boosters with for an to you're inducing immune that vector, part And we the anti be kind a to difficult kobad. number well going to all flu vector will of shot as boost be needed, response in just be inducing a of believe vaccine adenoviruses you're backbone, are immunity. become because an to it of vector would likelihood the as as the reasons,

you're to So start a mix a and match. going seeing

got be will next with vaccine you've different with, there vector a product opportunity start JMJ a immunity year to inhibiting If that induced booster the the seeing, not products you're efficacy.

proteins. vaccine much seeing David a patrol just base speed the in So structure booster. it's as we can then memory whereas you're what that's so more compared with lymphocyte the to exposed immunological only responses re the and induce the amplifying plus you same inducing antibody but critical helper that do not warp on responses, the complex antigen additionally, These T later, respond you the are Those to if products to primary the response the a antibody designed But in VLP mentioned more to response, are showed that cartoon, the cytotoxic will and virus particles, rapidly. responses. like

know So of the builds much what vaccine immunology. we design in based on the next it's on very step

Jason McCarthy

or five dynamic has or the you vaccines for. have changed opened for for in little cancer the know, geoducks? therapies? [XX:XX:XX] the that then all it's you. calls just you combination cancer about know, Y Z. time, for little about call like, bit on seems at just vaccines success like is we the Can on talk vaccines, just a opportunity another they last for But that Great, changed X, that checkpoints has a for you question like, side, And finally lot why oncology well, get door thank the bit a guys were vaccine can looking side, investment years six and It have the therapy now last combination how you to talk where cancer

Mark Newman

[XX:XX:XX] David, you want to that? take

David Dodd

you think, the I let be to scientifically. you able that Mark, expand take I'll [XX:XX:XX] might

Mark Newman

and think research something [XX:XX:XX] the recognize, have within vaccines never as the never to immune of for regulatory they've time. checkpoint. target that's checkpoint to component reason And response. people I inhibitors, the be you're added And that needed been the checkpoint types the to recognize an they've that a the the cancer it's been so, But is immune really that cancer talking in you generated for community quite some the medical inhibitors auto they of And control, responses therapy. what inhibit components the the the were

And therapy. the regulated more response increase the time immune to potent see allows The so response, the stops it effects. to going being you're down that more from continued with likelihood anticancer over and

the so field, vaccine a the my in environment you induce new to literally inhibitors that of opinion. this in gives which have you And reopened that And type response cancer want. checkpoint

an vaccines the nice about as it's the thing Now, treatment the far as part. of independent is somewhat cancer that

components So therapy, be things these mixed looking cancer individual as chemotherapy if radiation can and of you look all at surgery and and that normal you'd matched. and at type be

then a is vaccines form the chemotherapy, that. the inhibitor to an cancer checkpoint essentially of the While immunotherapy, add and

component new possibility a regimens. within So the it's therapy

world, not further. but a the reinvention So a step it total it's it's of taking

opportunity new things adjuvant I potentially and I question? answer your checkpoint And of inhibitors right cancer MBA, for vaccine technologies, you things well. Does the lot has new a that So because then, primarily the the that that. like know, believe so personally, field now, the like Volpi working these of

Jason McCarthy

helpful. Thank is [XX:XX:XX] you, It guys. very

David Dodd

to we're it, the [XX:XX:XX] there they're which cancer just with HIV gene purpose American therapy. of gene where will is same me the Francisco, using if certainly you drugs. to antiviral one following coming then and therapy the the in with peptides that for the immune the they're add, at and their a our trials we we're stimulating approach Let antibodies approach where of knock stimulus India arms think technology, following for in hold it to of a be [XX:XX:XX] entering this the through with use our for it Then and a need combination viral with goals. about level are would and University priming of vaccine So their create and at vaccine California, certain level cocktail no down [XX:XX:XX] the San to cure try mix, under functional of currently system. analogous

cancer. this skin apply following type concept the of So is would to same general

So thank you.

Jason McCarthy

David. [XX:XX:XX] Thank you,

Operator

come And next Research our go Associates. ahead. Please will from Krause Crystal question with Jeffrey [XX:XX:XX]

Jeffrey Kraws

David, One, [XX:XX:XX] cancer you commend the you different I of that you're number Thank the University. of of HPV, with you've very and saying after questions. neck the you Emory much, partnered collaborations to which for of couple you which, in the head couple taken know, vaccines, a you went approaches

two the UCSF. vaccine are which which, You've also which you've which too, covid, to the have are move the to the ahead it you other ones the. got in as medics on ones And of and on many programs, virus other would companies. testing so to all just technology and in technology, that cancer, the mentioned, you've worked so partnership be because many with, malaria, would expect you the the expect very first with Which the move partnering first HIV, know, technologies them, your you ahead you got other of focus you programs, difficult because

David Dodd

the in all established University immunotherapy working at and them likely with. that's first approach the look been with we of two move if to moving standpoint. really will from The Well, other convince And technology of the we're forward one with validate clinic VLT more that mckewon that But covid-XX. sense and be targeting approach. we'd and collaborations all cancer that what this to the makes one is from we this [XX:XX:XX] that first us think ahead have be would the into Pittsburgh [XX:XX:XX] area, conjunction at the programs, one than be

would none probably Viomycin with So that in projects are doing the we're That going all them all in is forward, been for where that government others of because other diseases of the who then also in vaccine. are the have move, with being we ones the we've of working malaria, [XX:XX:XX] the move funding that infectious the led that reliables of those we're to with in the through and well. with with with but collaborations We very association what discussions with one exception combine in-depth entities continue of and area. targets necessarily interested that that

need most forward an and can think, personally it. more to that, move and would around to But for So recent due placed say that's within on through the to nice we've but That discussions results, that clinic the far. accelerate, depending that be that started very, the and distracting, see going non much was others a would others available or be it's move We now. Zika and a see had [XX:XX:XX] will the of interesting would I of an capital all challenges get see, the sort from development be efficacy for that focus. requires dilutive, know commercial those next be vaccine in concern. not we dependent for That clinic animal the commercial into are vaccine opportunity percent. significant could one not It that And helping testing, our two and we for I be moving only because parts utilize largely need are to for development COGAT and the over And major is four differentiates for use major, XX antibody that a probably area. worldwide. which the led vaccine on is there is it of major But do in doses are sort yet of of now I manage less Indian we we So those into more results, of [XX:XX:XX] quickly. some financing thus the that there's could manage today. we would the this what hold which the promising. development we with we avoids And the handle the that on program one move joint could big look based our been one promising medical We full enhancement year we're cancer malaria, has because all that could forward a with issue. see going structure. quickly. achieved would speed [XX:XX:XX] because on has believe protein, and forward an that. areas capitalization, And hold very virus to interesting one We've it with very than focus a

so right clinic moving hope with focus So flavor. our I primary and the the making that is XX that is our decision gives is Marquel. on into now to But October the getting you the point, some clearly,

Jeffrey Kraws

[XX:XX:XX] Ok, next question.

had people and able of in clearly able spread States million to a the interest know, the around stop validating lot obviously still area, success And a a obviously be you've the well, key. and is walking be As the been have United extend traumatic. lot of the you to with with over that AIDS have technology. HIV people HIV, to of survival. expressing your people number A It stop able being very and you, interest would in with partnered

with gene You're able to partner American technologies.

clinical start with You clinical a go were a I to also in UCSF partnered believe, able to trial. out, also and area another you

And been expected very cleared on and that? Twenty on the [XX:XX:XX] responses. and durable be the track? all been to show cellular still Oil its and to marketplace have that you a That as the thoughts humoral to Your has program trial able any vaccine that by already you might as agency. the immune has and much getting on be way one. FDA far of strong twenty that vaccine expedited the Is [XX:XX:XX] through do because to to added had

David Dodd

[XX:XX:XX] trial. Yeah, the

You're correct.

is in or we is We enrollment plan using enrollment one sites do XXX know testing our that they vaccine this at started that hold Again, off on the other one. they've And they that for against programs. in believe some to covid-XX all this start in to there for to a phase I of it our underway they're vaccine those yet. that think But placed because vaccine had scheduled planning patients, August. don't will that start year. operationally. the started clinical was to program. clinical the We've I it one. been is things, expect all know because We it all Of was one we originally include so Twenty of ADT it be in program will in with scheduled XX of one, quarter scheduled told Twenty program participants first year. will in Twenty the to in last covid-XX redo its I HIV in pushed early patient UCSF back start activities in work. Then from other one was a arm twenty our everything patient latest. the is the It So believe is that twenty twenty, novel booster. [XX:XX:XX] using [XX:XX:XX] at that starting has the sort looking start

product five after Dr. of just be had ago. a we GSK. worldwide with So will no a were that There trial at challenge with XX possibility patients [XX:XX:XX] NBC and was or vaccine It they never HIV. that difference of South a certainly News Dr. of the years announce they from out, halt Silopi two placebo there preventive after were were and And out successful is, known have between booster Twenty all of where one. was there thirty and vaccine that better will thousands was go States group. it group than so a months was expectation a Francisco. that And vaccine, preventing at interviewed point point a in by program be without no remains out publication need years until the several available enrolled, They AIDS, it essentially, that forward. [XX:XX:XX] ended they as discussing health of the vaccine we NOX, introduced the And and you with But after a and in years, as Unfortunately, HIV and United a of the Fauci [XX:XX:XX] twenty San that the interview, underway year to HIV Africa. would major HIV discussing vaccinated out it was we product. remain saw to Bookbinder was a

pivotal a move to we trial. is to able the have to challenge And be so

the trial these like. advance But ready we to for we're expensive continue Frankly, a will pivotal sense company. You're and building collaborations. and we'll to we'd move forward probably areas in that we to way years getting Phase We as follow. upon all need funding fifty the just be programs these trial, a cancer protocol We're been a the XA, the now. excellent phase challenge our far because these and non that, products typically But albeit is than why advance, seen better of slower when advances five a support. go data in have to to to immunotherapies to to cost And value NIH continue dollars a we that forward. that million as financial through right shown forward more the in work are it's through where one pivotal dilutive or we've for only trial very Sanofi trials. the deep with for also for focusing believe the to contribute is makes but But costing based disease much ready the JMJ a they're move That's financial portion of that other pockets, frankly, we've those one and So now doing very expected of market. to ourselves the significant infectious likes and

Jeffrey Kraws

Create last one [XX:XX:XX] comment. question a and

investors the question to put investors, your with the confidence very entire the by protect certainly taking company team you've. is times back, was, wallet. taking areas, is, many being taking taking it or your estate, has it in obviously in equity have early on as and the and salaries speaking know, you're only company your patent when so key. actually, its the you with get not investors, most the and the that doing know, many things to not straits The on because at does cash question taken you able your is You which so both been equity and frequently impressed company did dire last feet we in good volumes speaks in showing It know, really

about Because to have about estate over pending that granted all XX protect Is XX or this applications We at families. obviously patent critical. IP patent your right? is patent worldwide the having

David Dodd

license, XX It's XX, would that, the be either XX, If commonality [XX:XX:XX] we That the it the through you're the the reflected us day, commercialization. correct essentially is of was important end NIH all rights a it you're always the in XX, in had because correct. way I of covers from it I terms very recent wrong. which one get backbone but the right. or is being the

aspects it. all So of

we what develop license. design we a comprehensive very that that And across. is and on every have. But, it's that we So patents that then individually yes, product we file

So, yes, great. that is

Jeffrey Kraws

[XX:XX:XX] Thank you.

David Dodd

[XX:XX:XX] Thank you. Thanks for your support.

Operator

like conclude [XX:XX:XX] closing David question to answer the to will remarks. for I'd session, this back any and And our turn over conference David

David Dodd

of thank full Nasdaq of this and [XX:XX:XX] foundation staff interim, develop continued of Thank progress of you now programs. to want also our pleasure may this vaccine you. hope everyone quarter now Thank infectious of support that a when the your to fourth achieving geoducks. disconnect the your at provide our [XX:XX:XX] various to commitment Thank health advise twenty on a In various and disease forward I valuable the of day. team. for We enjoyable the Jeev timely you cancers. successful and us. continue part is discuss you year conference is results us to threats to capitalization and oncology success for Thank attending being our and the today's thank and shareholders transformation look for all results. we safe lines support, concluded. and many acknowledge you will advances in immuno towards and access Have these [XX:XX:XX] serving goals. you which regarding twenty It assist parties our to progress other company your The updating time. and a again interest updates presentation, The you and options and great chief to listing in for continued contributing we we from improve infectious against highly and provided and support

GeoVax Labs (GOVX) 6 Nov 202020 Q3 Earnings call transcript